CASI vs ZLAB vs LEGN vs ZYME

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). Analysts rate Zai Lab Limited (ZLAB) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -4.

2%, compared to -99. 0% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: ZYME returned +83. 8% versus CASI's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 22β versus Zai Lab Limited's 1. 17β — meaning ZLAB is approximately -625% more volatile than CASI relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Legend Biotech Corporation (LEGN) is the more profitable company, earning -28.

8% net margin versus -137. 6% for CASI Pharmaceuticals, Inc. — meaning it keeps -28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LEGN leads at -13. 3% versus -138. 8% for CASI. At the gross margin level — before operating expenses — ZYME leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zymeworks Inc.

(ZYME) trades at 18. 1x forward P/E versus 116. 2x for Legend Biotech Corporation — 98. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LEGN: 105. 9% to $57. 89.

In this comparison, CASI (31.

1% yield) pays a dividend. ZLAB, LEGN, ZYME do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 22), 31. 1% yield). Both have compounded well over 10 years (CASI: -99. 0%, ZLAB: -33. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CASI is a small-cap income-oriented stock; ZLAB is a small-cap high-growth stock; LEGN is a small-cap high-growth stock; ZYME is a small-cap high-growth stock. CASI pays a dividend while ZLAB, LEGN, ZYME do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.